Want to see IN:WANBURY full AI Analyst Report?

Wanbury Limited (WANBURY) Price & Analysis

0 Followers

WANBURY Stock Chart & Stats

₹332.50

-₹2.65(-0.80%)

At close: Jul 27 4:00 PM EDT

₹332.50

-₹2.65(-0.80%)

Day’s Range― - ―

52-Week Range₹162.00 - ₹360.00

Previous CloseN/A

Volume188.34K

Average Volume (3M)8.26K

Market Cap

₹9.34B

Enterprise Value₹10.22K

Total Cash (Recent Filing)₹76.32M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)15.1

Beta1.83

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)17.29

Shares Outstanding34,939,400

10 Day Avg. Volume8,584

30 Day Avg. Volume8,255

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)4.96

Price to Sales (P/S)1.10

P/FCF Ratio-12.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)24.2

Revenue Forecast (FY)₹8.76B

Bulls Say, Bears Say

Bulls Say

Profitability TurnaroundThe return from a FY2023 loss to solid FY2026 operating and net margins indicates a meaningful earnings recovery. If maintained, improved profitability can strengthen internal funding capacity and support the company’s formulations and API operations.

Revenue RecoveryA sharp revenue step-up since FY2023, followed by continued FY2026 growth, indicates recovery in demand and/or execution across the formulations and API businesses. Sustained expansion would improve scale and support more resilient fixed-cost absorption.

Positive Equity BaseEquity moved from negative in earlier years to positive in FY2024 and expanded through FY2026. This repairs a key balance-sheet weakness and provides a stronger capital base, although it does not eliminate the burden of debt.

Bears Say

Weak Cash ConversionMinimal operating cash flow despite reported profit signals weak earnings-to-cash conversion. Deeply negative free cash flow in FY2025–FY2026 can increase dependence on external funding and constrain investment flexibility if working-capital pressure persists.

Elevated LeverageDebt remains larger than equity, leaving Wanbury more exposed to refinancing needs, interest burdens and earnings volatility. This reduces financial flexibility and can limit the company’s ability to fund growth or absorb operational setbacks.

Margin InstabilityThe earnings recovery is not yet supported by consistent cost control. Margin volatility and recent gross-margin compression could weaken the durability of reported profits, particularly when input costs, pricing or product mix change.

Wanbury Limited News

Wanbury Gains USFDA DMF Clearance for Metformin API, Bolstering Global Expansion

Wanbury Limited ( ($IN:WANBURY) ) has issued an announcement. Wanbury Limited announced that it has received a “No...

29d ago

Wanbury says USFDA audit at Tanuku plant poses no material business impact

An announcement from Wanbury Limited ( ($IN:WANBURY) ) is now available. Wanbury Limited has reported that the U.S....

1M ago

Wanbury Profit More Than Doubles in FY26 as Margins and Regulatory Profile Improve

Wanbury Limited ( ($IN:WANBURY) ) has shared an update. Wanbury Limited reported strong audited financial results for FY26,...

3M ago

Wanbury Begins Commercial Production of Key Anaesthetic API at Tanuku Plant

Wanbury Limited ( ($IN:WANBURY) ) just unveiled an announcement. Wanbury Limited has started commercial production of a key...

7M ago

Wanbury Files EOGM Voting Results with NSE and BSE

Wanbury Limited ( ($IN:WANBURY) ) just unveiled an announcement. Wanbury Limited has reported to the NSE and BSE...

8M ago

Wanbury Limited Announces Virtual EGM for January 2026

An announcement from Wanbury Limited ( ($IN:WANBURY) ) is now available. Wanbury Limited has announced that it will...

9M ago

Wanbury Limited Awaited Response on Financial Results Clarification

An announcement from Wanbury Limited ( ($IN:WANBURY) ) is now available. Wanbury Limited has been asked by the...

9M ago

Wanbury Limited Allots Shares Under ESOP

Wanbury Limited ( ($IN:WANBURY) ) has issued an announcement. Wanbury Limited announced the allotment of 15,000 equity shares...

10M ago

Wanbury Limited Allots Rs. 25 Crore Debentures to Tata Capital

Wanbury Limited ( ($IN:WANBURY) ) just unveiled an announcement. Wanbury Limited’s Day-to-Day Affairs Committee of the Board of...

11M ago

Wanbury Limited Announces 37th AGM and E-Voting Details

Wanbury Limited ( ($IN:WANBURY) ) just unveiled an update. Wanbury Limited has announced the scheduling of its 37th...

1y ago

WANBURY FAQ

What was Wanbury Limited’s price range in the past 12 months?

Wanbury Limited lowest stock price was ₹162.00 and its highest was ₹360.00 in the past 12 months.

What is Wanbury Limited’s market cap?

Wanbury Limited’s market cap is ₹9.34B.

When is Wanbury Limited’s upcoming earnings report date?

Wanbury Limited’s upcoming earnings report date is Oct 15, 2026 which is in 48 days.

How were Wanbury Limited’s earnings last quarter?

Wanbury Limited released its earnings results on Aug 11, 2026. The company reported ₹0.928 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Wanbury Limited overvalued?

According to Wall Street analysts Wanbury Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wanbury Limited pay dividends?

Wanbury Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Wanbury Limited dividends here

What is Wanbury Limited’s EPS estimate?

Wanbury Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wanbury Limited have?

Wanbury Limited has 34,939,400 shares outstanding.

What happened to Wanbury Limited’s price movement after its last earnings report?

Wanbury Limited reported an EPS of ₹0.928 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.779%.

Which hedge fund is a major shareholder of Wanbury Limited?

Currently, no hedge funds are holding shares in IN:WANBURY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wanbury Limited

Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formulations addresses numerous therapeutic areas, including women's health, bone and joint conditions, hematological disorders, diabetes management, nutritional support, gastrointestinal ailments, post-stroke recovery, infectious diseases, respiratory issues, inflammatory conditions, pain relief, and general medicine, marketed under approximately 70 different brands. Additionally, Wanbury supplies APIs vital for medicines treating diabetes, pain, depression, allergies, inflammation, arthritis, thrombosis, epilepsy, and hypertension. The company extends its reach beyond India through product exports. Originally incorporated in 1988 as Pearl Organics Limited, the firm was rebranded as Wanbury Limited in 2004 and maintains its corporate headquarters in Navi Mumbai, India.